Populations

Types of Research

Geography

Dataset

EPAR Technical Report #345
Review of Literature on Factors Affecting Private Sector Investment in Global Health R&D
Publication Date: 12/01/2017
Type: Literature Review
Abstract

The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.

Technical Report, Technical Report Executive Summary
EPAR Technical Report #359
Review of Long-Term Impacts of Cash Transfer Programs
Publication Date: 11/13/2017
Type: Literature Review
Abstract

Cash transfer programs are interventions that directly provide cash to target specific populations with the aim of reducing poverty and supporting a variety of development outcomes. Low- and middle-income countries have increasingly adopted cash transfer programs as central elements of their poverty reduction and social protection strategies. Bastagli et al. (2016) report that around 130 low- and middle-income countries have at least one UCT program, and 63 countries have at least one CCT program (up from 27 countries in 2008). Through a comprehensive review of literature, this report primarily considers the evidence of the long-term impacts of cash transfer programs in low- and lower middle-income countries. A review of 54 reviews that aggregate and summarize findings from multiple studies of cash transfer programs reveals largely positive evidence on long-term outcomes related to general health, reproductive health, nutrition, labor markets, poverty, and gender and intra-household dynamics, though findings vary by context and in many cases overall conclusions on the long-term impacts of cash transfers are mixed. In addition, evidence on long-term impacts for many outcome measures is limited, and few studies explicitly aim to measure long-term impacts distinctly from immediate or short-term impacts of cash transfers.

Technical Report, Results Coding
EPAR Technical Report #338
Policy and Economic Considerations for the Provision of Global Public Goods: Biomedical Research and Development
Publication Date: 05/19/2017
Type: Literature Review
Abstract

The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.

Poster Presentation
EPAR Technical Report #200
Herbicide Resistant Cassava
Publication Date: 08/24/2012
Type: Literature Review
Abstract

This report investigates the potential environmental and socio-economic benefits and costs of glyphosate resistant cassava.  Glyphosate resistant crops (also referred to as glyphosate tolerant) have been rapidly adopted by a number of crop producers because they simplify and/or reduce the cost of weed management. Glyphosate resistant crops also provide external environmental benefits by promoting reduced tillage agriculture, decreasing erosion and increasing soil health. However, glyphosate resistant crops also have some environmental costs, potentially leading to increased use of herbicides and environmental contamination. Because transgenic glyphosate resistant cassava is not currently in use, literature on its potential environmental and socioeconomic costs and benefits is limited. Therefore, this report draws on the literature for glyphosate resistant crops that are in current use, including maize, soybeans, sugar beets and canola (rapeseed). We find that socioeconomic and environmental impacts of glyphosate resistant crops differ by crop-type, agroecological conditions, production systems and local regulatory structure. Therefore, some benefits and costs associated with other glyphosate resistant crops may not be applicable to glyphosate resistant cassava. 

Literature Review